Hepatocellular carcinoma cost-effectiveness of therapy

Hepatocellular carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes of Hepatocellular carcinoma
Differentiating Hepatocellular carcinoma from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
Diagnostic study of choice
History and symptoms
Physical Examination
Lab Tests
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hepatocellular carcinoma cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hepatocellular carcinoma cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hepatocellular carcinoma cost-effectiveness of therapy
CDC on Hepatocellular carcinoma cost-effectiveness of therapy
Hepatocellular carcinoma cost-effectiveness of therapy in the news
Blogs on Hepatocellular carcinoma cost-effectiveness of therapy
Directions to Hospitals Treating Hepatocellular carcinoma
Risk calculators and risk factors for Hepatocellular carcinoma cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Hepatocellular carcinoma (HCC) most commonly appears in a patient with chronic viral hepatitis (hepatitis B or hepatitis C, 20%) or with cirrhosis (about 80%). These patients commonly undergo surveillance with ultrasound due to the cost-effectiveness.

References

Template:WikiDoc Sources